- Home
- NWN vs KNSA Comparison
NWN vs KNSA Comparison
Compare NWN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWN
- KNSA
- Stock Information
- Founded
- NWN 1859
- KNSA 2015
- Country
- NWN United States
- KNSA United Kingdom
- Employees
- NWN N/A
- KNSA N/A
- Industry
- NWN Oil/Gas Transmission
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- NWN Utilities
- KNSA Health Care
- Exchange
- NWN Nasdaq
- KNSA Nasdaq
- Market Cap
- NWN 1.5B
- KNSA 1.7B
- IPO Year
- NWN N/A
- KNSA 2018
- Fundamental
- Price
- NWN $39.84
- KNSA $20.59
- Analyst Decision
- NWN Strong Buy
- KNSA Strong Buy
- Analyst Count
- NWN 2
- KNSA 5
- Target Price
- NWN $43.50
- KNSA $36.60
- AVG Volume (30 Days)
- NWN 200.8K
- KNSA 272.9K
- Earning Date
- NWN 11-12-2024
- KNSA 10-29-2024
- Dividend Yield
- NWN 4.92%
- KNSA N/A
- EPS Growth
- NWN N/A
- KNSA N/A
- EPS
- NWN 2.06
- KNSA N/A
- Revenue
- NWN $1,137,832,000.00
- KNSA $384,098,000.00
- Revenue This Year
- NWN $0.46
- KNSA $60.05
- Revenue Next Year
- NWN $7.23
- KNSA $36.32
- P/E Ratio
- NWN $19.37
- KNSA N/A
- Revenue Growth
- NWN N/A
- KNSA 54.41
- 52 Week Low
- NWN $34.82
- KNSA $16.56
- 52 Week High
- NWN $44.25
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- NWN 35.06
- KNSA 40.95
- Support Level
- NWN $39.12
- KNSA $19.97
- Resistance Level
- NWN $41.83
- KNSA $20.85
- Average True Range (ATR)
- NWN 0.75
- KNSA 0.69
- MACD
- NWN -0.41
- KNSA 0.03
- Stochastic Oscillator
- NWN 12.36
- KNSA 35.61
About NWN Northwest Natural Holding Company
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company generates its revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.